Skip to main content
TLRYTilray Brands, Inc.Sell5.4·$4.55+0.77%
SellModerate Confidence
Investment thesis

Tilray Brands shows an extreme risk/reward skew with 117% analyst upside and a passed asymmetry gate, but quality below the engine's floor, a confirmed downtrend with a death-cross block, and high short interest keep the engine's recommendation at exit.

Thesis pillars

  • Quality Below Floor Value TrapStable
  • High Asymmetry Large Analyst UpsideDeteriorating
  • Failed Momentum Confirmed DowntrendStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Tilray Brands, Inc. (TLRY) Stock Analysis

Range Bound setup · Inst Constrain edge

SellVALUE-TRAP 1/5ValueGrowthModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Engine safety override at $4.55: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.

Tilray Brands is a global lifestyle consumer products company operating across four segments — Beverage, Cannabis, Distribution, and Wellness — with brands including SweetWater Brewing, Breckenridge Brewery, Manitoba Harvest, and a portfolio of Canadian cannabis brands. The... Read more

QualityF-score4 / 9FCF yield-4.03%
Stop $4.23Target $6.82(analyst − 13%)A.R:R 4.8:1
Analyst target$7.84+72.4%8 analysts
$6.82our TP
$4.55price
$7.84mean
$19

Sell if holding. Engine safety override at $4.55: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

10-K grounded · weekly refresh

About Tilray Brands, Inc.

About Tilray Brands, Inc.

Tilray Brands generated $821.3 million in total net revenue for the fiscal year ended May 31, 2025, spread across four segments: Distribution (33%), Cannabis (30%), Beverage (29%), and Wellness (8%). Within the Cannabis segment, Canadian adult-use cannabis sales accounted for 91% of segment revenue, with the remainder split between Canadian medical cannabis, wholesale, and international cannabis sales. The company markets over a dozen beverage, cannabis, and wellness brands, including SweetWater Brewing and Manitoba Harvest.

Tilray earns revenue from four distinct business lines: Beverage (production, marketing, and sale of craft beer and spirits under brands including SweetWater Brewing, Breckenridge Brewery, and Atwater), Cannabis (cultivation, production, distribution, and sale of medical and adult-use cannabis, primarily in Canada), Distribution (purchase, resale, and distribution of third-party pharmaceutical and wellness products, mainly through its German subsidiary CC Pharma), and Wellness (production and marketing of hemp-based foods under the Manitoba Harvest and Humble Seed brands). The company expanded its U.S. beverage platform through two acquisitions of craft brewing brands — Craft Acquisition I from Anheuser-Busch in September 2023 and Craft Acquisition II from Molson Coors in September 2024 — a diversification strategy management frames explicitly as a way to access the U.S. market ahead of, or independent from, federal cannabis legalization. International medical cannabis is supplied to patients in over 20 countries through EU-GMP production facilities in Portugal and Germany.

Show full overview

Tilray's cannabis business remains structurally exposed to a single regulatory threshold that has not yet been crossed: the 10-K states that in the event recent efforts to reschedule cannabis as a Schedule III substance in the U.S. prevail and enable Tilray to enter the medical cannabis business, the company believes its existing leadership position in Canada, Europe, and Australia would let it launch U.S. medical cannabis operations quickly. Until that rescheduling or federal legalization occurs, Tilray's U.S. cannabis-market access is confined to its beverage, wellness, and distribution businesses rather than cannabis itself — meaning the timing of a single U.S. federal policy decision, not a competitive or operational factor, is what would unlock the segment where Tilray already claims category leadership in Canada.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Tilray Brands, Inc.'s most recent 10-K filing, extracted August 9, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-09-03
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Oct 8, 202635d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Canadian adult-use cannabis (91.0%)
Quality below floor (1.9 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)10.0
Mkt Cap$622M
EV/EBITDA129.4
Profit Mgn-13.3%
ROE-6.8%
Rev Growth-7.8%
Beta1.92
DividendNone
Rating analysts17

Quality Signals

Piotroski F4/9

Options Flow

P/C1.01bearish
IV74%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMProductDistribution business33%
    10-K Item 1: 'Distribution business | | | 271,228 | | | | 33 | %'
  • HIGHProductCanadian adult-use cannabis91%
    10-K Item 1: 'Revenue from Canadian adult-use cannabis | | | 224,048 | | | | 91 | %'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -13.3%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Gross Margin
1.7
Moat
3.2
Piotroski F
4.4
Current Ratio
7.6
Cash-burning: FCF -3% of revenueNo competitive moatQuality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
News Activity
8.0
Earnings concerns: 0B/2M

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
2.1
Ma Position
3.0
Macd
3.5
Rsi
4.5
Obv
6.2
Below 200-MA, MA slope -18.4%/30d — confirmed downtrend
GatesMomentum 3.9<4.5Death cross (50MA < 200MA)A.R:R 4.8 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 35d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Speculative
RSI
46 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $4.33Resistance $4.95

Price Targets

$4
$7
A.Upside+50.0%
A.R:R4.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.9 < 4.0)
! momentum at 3.9 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

M
M
M
M
0/4 beats
Next Earnings2026-10-08 (35d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TLRY stock a buy right now?

Sell if holding. Engine safety override at $4.55: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $4.23. Score 5.4/10, moderate confidence.

What is the TLRY stock price target?

Take-profit target: $6.82 (+50.0% upside). Prior stop was $4.23. Stop-loss: $4.23.

What are the risks of investing in TLRY?

Concentration risk — Product: Canadian adult-use cannabis (91.0%); Quality below floor (1.9 < 4.0).

Is TLRY overvalued or undervalued?

Tilray Brands, Inc. trades at a P/E of N/A (forward 10.0). TrendMatrix value score: 9.6/10. Verdict: Sell.

What do analysts say about TLRY?

17 analysts cover TLRY with a consensus score of 3.6/5. Average price target: $8.

What does Tilray Brands, Inc. do?Tilray Brands is a global lifestyle consumer products company operating across four segments — Beverage, Cannabis,...

Tilray Brands is a global lifestyle consumer products company operating across four segments — Beverage, Cannabis, Distribution, and Wellness — with brands including SweetWater Brewing, Breckenridge Brewery, Manitoba Harvest, and a portfolio of Canadian cannabis brands. The company generated $821.3 million in total net revenue for fiscal 2025, led by Distribution (33%), Cannabis (30%), and Beverage (29%), with Canadian adult-use cannabis representing 91% of Cannabis segment revenue.

Related stocks: BCRX (BioCryst Pharmaceuticals, Inc.) · IRWD (Ironwood Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · KMDA (Kamada Ltd.) · BHC (Bausch Health Companies Inc.)
Home Stocks TLRY

Latest news

Latest News

Benzinga8h agoProduct
Benzinga6d ago
Benzinga14d agoProduct
Benzinga17d agoProduct
Benzinga31d ago
Benzinga37d ago
Benzinga37d ago
Benzinga45d agoProduct
Benzinga51d agoAnalyst
Benzinga56d agoProduct
Benzinga66d agoMerger Acquisition